A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 712-719

  Wang, Haijuan ^a   Pei, Wei ^a   Luan, Qingchun ^a,b   Ma, Fei ^a   Zhou, Shaohua ^c   Zhao, Zhilong ^c   Meng, Xiting ^a   Zhang, Xueyan ^a   Liang, Xiao ^a   Chen, Yan ^b   Zhan, Qimin ^a   Lin, Chen ^a   Qian, Haili ^a   Zhao, Ping ^a  

^a CANCER HOSPITAL   (China)

^b Hebei Union University   (China)

^c DALIAN UNIVERSITY   (China)

Author keywords

Adenovirus; Apoptosis; Gene therapy; Pancreatic cancer; PUMA

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; FLUOROURACIL; GEMCITABINE; PROTEIN P53; PUMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEASIBILITY STUDY; GENE EXPRESSION; GENE THERAPY; HUMAN; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEASIBILITY STUDIES; FLUOROURACIL; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863480695     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20552     Document Type: Article

References (33)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17; PMID:20427809; http://dx.doi.org/10.1056/NEJMra0901557.
2. Koliopanos A, Avgerinos C, Paraskeva C, Touloumis Z, Kelgiorgi D, Dervenis C. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 2008; 7:345-56; PMID:18693168.
3. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2:985-91; PMID:8782455; http://dx.doi.org/10.1038/nm0996- 985.
4. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2:1222; PMID:20463003; http://dx.doi.org/10.1101/ cshperspect.a001222.
5. Thomas SM, Grandis JR. The current state of head and neck cancer gene therapy. Hum Gene Ther 2009; 20:1565-75; PMID:19747066; http://dx.doi.org/10. 1089/hum.2009.163.
6. Vattemi E, Claudio PP. The feasibility of gene therapy in the treatment of head and neck cancer. Head Neck Oncol 2009; 1:3; PMID:19284676; http://dx.doi.org/10.1186/1758-3284-1-3.
7. Abuzeid WM, Li D, O'Malley BW Jr. Gene therapy for head and neck cancer. Adv Otorhinolaryngol 2011; 70:141-51; PMID:21358197; http://dx.doi.org/10.1159/ 000322490.
8. Sun Y, Liu JH, Jin L, Lin SM, Yang Y, Sui YX, et al. Overexpression of the Beclin1 gene upregulates chemosensitivity to anti-cancer drugs by enhancing therapy-induced apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett 2010; 294:204-10; PMID:20207475; http://dx.doi.org/10.1016/j.canlet.2010.02.001.
9. Chen K, Luo Z, Li Z, Liu Y, Zhao Q. PERP gene therapy attenuates lung cancer xenograft via inducing apoptosis and suppressing VEGF. Cancer Biol Ther 2011; 12:12; PMID:22236877.
10. Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001; 98:11318-23; PMID:11572983; http://dx.doi.org/10.1073/pnas.201208798.
11. Bouillet P, Strasser A. BH3-only proteins - evolutionarily conserved proapoptotic Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 2002; 115:1567-74; PMID:11950875.
12. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7:673-82; PMID:11463391; http://dx.doi.org/10.1016/S1097-2765(01)00213-1.
13. Yu J, Yue W, Wu B, Zhang L. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 2006; 12:2928-36; PMID:16675590; http://dx.doi.org/10.1158/1078-0432.CCR-05-2429.
14. Ito H, Kanzawa T, Miyoshi T, Hirohata S, Kyo S, Iwamaru A, et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 2005; 16:685-98; PMID:15960600; http://dx.doi.org/10.1089/ hum.2005.16.685.
15. Wang H, Qian H, Yu J, Zhang X, Zhang L, Fu M, et al. Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs. Cancer Biol Ther 2006; 5:380-5; PMID:16481741; http://dx.doi.org/10.4161/cbt.5.4.2477.
16. Chen Y, Qian H, Wang H, Zhang X, Fu M, Liang X, et al. Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents. Gynecol Oncol 2007; 107:505-12; PMID:17884151; http://dx.doi.org/10.1016/j.ygyno.2007.08.007.
17. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ 2004; 329:668-73; PMID:15374918; http://dx.doi.org/10.1136/bmj.329.7467.668.
18. Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008; 26:3511-6; PMID:18640932; http://dx.doi.org/10.1200/JCO.2007.15.8782.
19. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26:3503-10; PMID:18640931; http://dx.doi.org/10.1200/JCO.2007.15. 8469.
20. Shi X, Liu S, Kleeff J, Friess H, Büchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62:354-62; PMID:12138244; http://dx.doi.org/10.1159/000065068.
21. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13:1351-9; PMID:16763616; http://dx.doi.org/10. 1038/sj.cdd.4401987.
22. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, et al. Induction of p53 upregulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 2005; 11:1863-9; PMID:15756011; http://dx.doi.org/10.1158/1078- 0432.CCR-04-1372.
23. Xu B, Wang BJ, Li AM, Lock R. Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia. Zhongguo Dang Dai Er Ke Za Zhi 2006;8:151-4; PMID:16613713.
24. Sun Q, Sakaida T, Yue W, Gollin SM, Yu J. Chemosensitization of head and neck cancer cells by PUMA. Mol Cancer Ther 2007; 6:3180-8; PMID:18089712; http://dx.doi.org/10.1158/1535-7163.MCT-07-0265.
25. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 upregulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis and patient survival. Cancer Res 2006; 66:9221-6; PMID:16982766; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-3633.
26. Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer 2007; 109:188-97; PMID:17149756; http://dx.doi.org/10.1002/cncr.22416.
27. Wang R, Wang X, Li B, Lin F, Dong K, Gao P, et al. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 2009; 117:45-54; PMID:18791823; http://dx.doi.org/10.1007/s10549-008-0163- 6.
28. Giladi N, Dvory-Sobol H, Sagiv E, Kazanov D, Liberman E, Arber N. Gene therapy approach in prostate cancer cells using an active Wnt signal. Biomed Pharmacother 2007; 61:527-30; PMID:17904788; http://dx.doi.org/10.1016/j.biopha. 2007.08.010.
29. Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010; 37:1621-6; PMID:21042732.
30. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993; 69:151-60; PMID:8513440; http://dx.doi.org/10. 1016/0304-3835(93)90168-9.
31. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025-33; PMID:8187092.
32. Zhang K, Chen D, Wang X, Zhang S, Wang J, Gao Y, et al. RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via Upregulating PUMA. Int J Mol Sci 2011; 12:385-400; PMID:21339993; http://dx.doi.org/10.3390/ijms12010385.
33. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95:2509-14; PMID:9482916; http://dx.doi.org/10.1073/pnas.95.5.2509.